Loading...

Home
ETF
IMMP

IMMP

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

IMMP News

Immutep's TACTI-004 Trial Reaches 50% Enrollment Milestone

Feb 06 2026Newsfilter

Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results

Dec 22 2025Benzinga

ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections

Dec 15 2025Yahoo Finance

Immutep Secures Exclusive Eftilagimod Alfa Licensing Deal with Dr. Reddy's for $20M Upfront Payment

Dec 08 2025Newsfilter

Highlights of ASX Penny Stocks: Immutep and Two Other Notable Selections

Nov 16 2025Yahoo Finance

EFTISARC-NEO Phase II Trial Achieves Primary Endpoint for Neoadjuvant Efti in Soft Tissue Sarcoma, Findings Revealed at ESMO Congress 2025

Oct 20 2025Newsfilter

Immutep Provides Update on TACTI-004 (KEYNOTE-F91) Phase III Trial for First-Line Treatment of Non-Small Cell Lung Cancer

Oct 09 2025Newsfilter

Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement

Sep 10 2025NASDAQ.COM

Immutep Gets Positive Feedback From FDA On Late-Stage Clinical Development Of Eftilagimod Alfa

Aug 05 2025NASDAQ.COM

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 15 2025Benzinga

Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 15 2025Newsfilter

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

May 06 2025Benzinga

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

Mar 20 2025Newsfilter

Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity

Mar 07 2025Business Insider

Patient Enrolment Completed for INSIGHT-003

Jan 06 2025Newsfilter

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17 2024Newsfilter